RBC
TEVA icon

Roble Belko & Company’s Teva Pharmaceuticals TEVA Stock Holding History

Roble Belko & Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$4K – 328
2017
Q3 		$4K Hold
200
– – ﹤0.01% 236
2017
Q2 		$7K Hold
200
– – ﹤0.01% 221
2017
Q1 		$6K Hold
200
– – ﹤0.01% 252
2016
Q4 		$7K Sell
200
-580
-74% -$23.2K ﹤0.01% 252
2016
Q3 		$36K Buy
780
+355
+84% +$18.5K 0.02% 127
2016
Q2 		$21K Buy
+425
New +$22.6K 0.01% 154

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Roble Belko & Company's TEVA Position: Q4 2017 in Review

Roble Belko & Company sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 200 shares — an estimated $4K sold.

Roble Belko & Company first reported a position in TEVA in Q2 2016 and held it in 6 quarters. The position peaked at $36K in Q3 2016. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Roble Belko & Company reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Roble Belko & Company sold 200 Teva Pharmaceuticals shares in Q4 2017, an estimated $4K.
  • Roble Belko & Company first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 6 quarters.
  • Roble Belko & Company's Teva Pharmaceuticals position peaked at $36K in Q3 2016.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Roble Belko & Company's 13F filing for Q4 2017, filed 30 Jan 2018.